AI-curated court updates, legal developments, and practice-area insights for Indian legal professionals.
The weighted average lending rate (WALR) on fresh rupee loans of scheduled commercial banks stood at 8.61% in August 2026, up slightly from 8.52% the previous month. The WALR on outstanding loans declined marginally to 8.96%.
The Reserve Bank of India conducted a 4-day Variable Rate Reverse Repo (VRRR) auction on October 1, 2026, with a notified amount of ₹2,00,000 crore. The auction was fully subscribed, with ₹1,68,055 crore accepted at a uniform cut-off rate of 5.24%.
CBIC notifies Special Notified Zone at Surat Diamond Bourse for rough diamond trade activities.
CAAR Mumbai held MILDS Block 2 aircraft components eligible for customs duty exemption with Condition No. 17 certification.
CAAR Mumbai classified embedded Wi-Fi, cellular, and GNSS modules under CTI 8517 79 90, permitting nil BCD under Notification 57/2017.
CAAR Mumbai ruled kitchen exhaust hoods over 120 cm with integral fans fall under CTH 8414 80 90, not 8414 59 90, affecting duty rates.
Section 52 restricts securities premium use to bonus issue, expense write-off, issue cost, redemption premium, and buy-back.
Analysis of Turquand’s rule, Section 118, SS-1 and constructive notice in contested board resolution validity.
Second Amendment Directions issued for Payments Banks to standardise investment valuation. Ensures consistent and transparent portfolio management.
The RBI has modified its 2022 ATM cassette swap guidelines, allowing bank boards to delegate monitoring responsibility. Ensures smoother implementation while maintaining security oversight.
The Reserve Bank of India (RBI) has withdrawn outdated circulars on currency management as part of its regulatory rationalisation initiative. Banks must comply with the updated framework effective October 1, 2026.
RBI conducted yield-based auctions of state government securities on September 29, 2026, raising ₹3,400 crore. Assam and Bihar re-issued securities with yields between 7.87% and 7.97%.
The IPO’s 2026 Draft Guidelines face strong critique for misquoting law and risking disruption to patent prosecution in pharmaceuticals; calls grow for immediate revision.